Revance Therapeutics, Inc. (RVNC): Price and Financial Metrics
Today's Latest Price: $25.96 USD
Oct 28 11:02am Add RVNC to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
RVNC Stock Summary RVNC's price/sales ratio is 3,370.12; that's higher than the P/S ratio of 99.67% of US stocks. With a year-over-year growth in debt of 555.11%, Revance Therapeutics Inc's debt growth rate surpasses 96.71% of about US stocks. As for revenue growth, note that RVNC's revenue has grown -84.27% over the past 12 months; that beats the revenue growth of only 1.55% of US companies in our set. If you're looking for stocks that are quantitatively similar to Revance Therapeutics Inc, a group of peers worth examining would be ADVM, AUPH, VTVT, CRMD, and GERN. RVNC's SEC filings can be seen here. And to visit Revance Therapeutics Inc's official web site, go to www.revance.com.
RVNC Price/Volume Stats
Revance Therapeutics, Inc. (RVNC) Company Bio
Revance Therapeutics is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company was founded in 1999 and is based in Newark, California.
RVNC Latest News Stream
All News Types
Acquisition Commentary Corp. News Cramer Debt Offering Downgrade Earnings Hedge Fund Mgmt Change New Coverage (Bullish) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering
Loading, please wait...
Latest RVNC News From Around the Web
Below are the latest news stories about Revance Therapeutics Inc that investors may wish to consider to help them evaluate RVNC as an investment opportunity.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnos...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...
Revance Therapeutics, Inc. (RVNC) Q2 2020 Earnings Conference Call August 06, 2020 04:30 PM ET Company Participants Jeanie Herbert - Head, Investor Relations & Corporate Communications Mark Foley - President & Chief Executive Officer Dustin Sjuts - Chief Commercial Officer, Aesthetics & Therapeutics Toby Schilke - Chief Financial Officer Abhay...
Read More 'RVNC' Stories Here
RVNC Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.7822 seconds.